Alpha-1 antitrypsin deficiency (A1AD) is an inherited disorder potentially affecting millions of people in the U.S. The disease results from deficiency of a glycoprotein responsible for the regulation of inflammation, coagulation, and repair mechanisms in the body. This deficiency can cause "early decade" emphysema, liver cirrhosis, primary liver cancer, and multiple other health problems. It is postulated 80,000 to 100,000 people in the U.S. have severe A1AD and 25 million are carriers. Severely deficient persons are at highest risk for health complications. but carriers also inherit an increased risk. A Mayo Clinic study in 2001 linked A1AD to MSI-H colorectal cancer, which comprises 15% of all colorectal cancers. A1AD is the most common genetic cause of liver transplants in children and those with cirrhosis from A1AD have a significant risk of developing primary liver cancer. Estimates indicate that 1 to 3% of all chronic obstructive pulmonary disease (COPD) patients have severe A1AD. Currently poor awareness of this disease, both by providers and the public sector, contributes to misdiagnoses and incomplete treatment for patients. Awareness and early detection of this disorder is key to vital intervention, support, and treatment.

Section Description

We are pleased to present the abstracts from SGNA's 33rd Annual Course, SGNA on a Mission: Exceeding Expectations. The diversity of these topics certainly reflects the richness and breadth of our specialty. In keeping with the tradition of the Annual Course, we hope the following abstracts will encourage discussions for improving nursing practice and patient care outcomes.